HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a $4.00 price target on the stock.
Separately, Benchmark reaffirmed a "speculative buy" rating and set a $3.00 target price on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Unicycive Therapeutics presently has an average rating of "Buy" and a consensus price target of $5.50.
Get Our Latest Research Report on Unicycive Therapeutics
Unicycive Therapeutics Price Performance
UNCY traded down $0.04 during trading on Wednesday, hitting $0.74. The stock had a trading volume of 1,648,587 shares, compared to its average volume of 1,465,099. The company has a 50 day moving average price of $0.65 and a 200-day moving average price of $0.49. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.82. The firm has a market cap of $76.81 million, a price-to-earnings ratio of -0.76 and a beta of 2.30.
Institutional Investors Weigh In On Unicycive Therapeutics
A number of large investors have recently bought and sold shares of the company. Bleakley Financial Group LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at approximately $33,000. Great Point Partners LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at $3,491,000. Acuta Capital Partners LLC bought a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $807,000. Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter worth $2,040,000. Finally, XTX Topco Ltd bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter worth $29,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.
About Unicycive Therapeutics
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Further Reading
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
